Free Trial

ARCA biopharma Q3 2023 Earnings Report

ARCA biopharma Earnings Headlines

While Buffett Buys Oil, This ETF Pays 22% Yields
Warren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occidental and Chevron) pay modest dividends of 1.47% and 4%, we've found a way for regular investors to potentially earn a much bigger income stream from the energy boom.
See More ARCA biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ARCA biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ARCA biopharma and other key companies, straight to your email.

About ARCA biopharma

ARCA biopharma (NASDAQ:ABIO), a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure. It is developing Recombinant Nematode Anticoagulant Protein c2, a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. The company has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.

View ARCA biopharma Profile

More Earnings Resources from MarketBeat